Egelston, C., Guo, W., Yost, S., Lee, J. S., Rose, D., Avalos, C., . . . Yuan, Y. (2021). Pre-existing effector T-cell levels and augmented myeloid cell composition denote response to CDK4/6 inhibitor palbociclib and pembrolizumab in hormone receptor-positive metastatic breast cancer. J Immunother Cancer.
Citação norma ChicagoEgelston, Colt, et al. "Pre-existing Effector T-cell Levels and Augmented Myeloid Cell Composition Denote Response to CDK4/6 Inhibitor Palbociclib and Pembrolizumab in Hormone Receptor-positive Metastatic Breast Cancer." J Immunother Cancer 2021.
Citação norma MLAEgelston, Colt, et al. "Pre-existing Effector T-cell Levels and Augmented Myeloid Cell Composition Denote Response to CDK4/6 Inhibitor Palbociclib and Pembrolizumab in Hormone Receptor-positive Metastatic Breast Cancer." J Immunother Cancer 2021.